Stock Price Analysis of Walgreens Boots Alliance, Inc. (WBA)

Dec 08, 2017, 01:39

Investors will get a clear idea on how much they can earn per share on each of the outstanding shares of common stock. (WBA) - averaging the work of different analysts - reveals a mean PT of $84.96/share.

Analysts await Walgreens Boots Alliance, Inc. Robert W. Baird reissued an "outperform" rating and issued a $96.00 price objective on shares of Walgreens Boots Alliance in a report on Monday, March 27th. Finally, Mizuho set a $94.00 target price on shares of Walgreens Boots Alliance and gave the stock a "buy" rating in a report on Tuesday, October 24th. UBS reaffirmed a "buy" rating and set a $96.00 target price (down from $97.00) on shares of Walgreens Boots Alliance in a report on Wednesday, August 23rd. BidaskClub cut shares of Walgreens Boots Alliance from a hold rating to a sell rating in a research report on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company's stock. WBA has a net profit margin of 3.40% and is more profitable than the average company in the Drug Stores industry.

Several other hedge funds also recently made changes to their positions in WBA. The company's market cap is $70.03 Billion, and the average volume is 8.04 Million. WBA trades with a P/S ratio of 0.6. During the last 52 weeks, the (NASDAQ:WBA) price has been as high as $88 and as low as $63.82.

Walgreens Boots Alliance (NASDAQ:WBA) last posted its quarterly earnings results on Wednesday, October 25th. They expect $1.26 EPS, up 14.55% or $0.16 from last year's $1.1 per share. The Higher end of the revenue forecast is $30.66 Billion, while the Lower end of the forecast is $28.35 Billion. Upon completion, Walgreens Boots Alliance said it would account for this stake as an equity method investment. The company's quarterly revenue was up 5.3% compared to the same quarter a year ago.

Walgreens Boots Alliance (WBA) now has a 50-day Moving Average of 70.16, the 200-day Moving Average is 78.98, and the 7-day is noted at 71.27.

ROA ratio indicates how profitable a company is relative to its total assets. This repurchase authorization permits the pharmacy operator to purchase shares of its stock through open market purchases. Shareholders of record on Thursday, May 18th will be paid a $0.375 dividend. The ex-dividend date of this dividend is Friday, November 10th. This represents a $1.60 dividend on an annualized basis and a yield of 2.25%. Walgreens Boots Alliance's dividend payout ratio is now 39.68%.

In other news, Director John Anthony Lederer acquired 20,000 shares of Walgreens Boots Alliance stock in a transaction that occurred on Thursday, October 26th. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The average investment recommendation for WBA, taken from a group of Wall Street Analysts, is 2.20, or a buy. The disclosure for this purchase can be found here. Insiders own 14.80% of the company's stock.

Other institutional investors have also recently added to or reduced their stakes in the company. As per Monday, August 24, the company rating was downgraded by Zacks. Commonwealth Bank of Australia increased its holdings in shares of Walgreens Boots Alliance by 139.5% during the 2nd quarter. Jefferies maintained Walgreens Boots Alliance, Inc. Simpson Thacher & Bartlett LLP and Weil, Gotshal & Manges LLP are serving as legal advisors to KKR and Walgreens Boots Alliance, Inc., respectively. Orrstown Financial Services Inc. increased its position in Walgreens Boots Alliance by 13.9% in the first quarter. Private Vista LLC now owns 583,185 shares of the pharmacy operator's stock valued at $140,000 after acquiring an additional 574,218 shares in the last quarter.

Walgreens Boots Alliance (NASDAQ:WBA) last released its quarterly earnings data on Wednesday, April 5th. If you are reading this news story on another site, it was stolen and reposted in violation of United States and global copyright and trademark laws. The original version of this article can be viewed at "We have had a presence in China for around 10 years, initially through Alliance Boots, and we are excited about the opportunity to further invest in the country's fast growing retail pharmacy sector". The Company's products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand).